Key facts
- Proscia’s last known valuation is $150.0M (Mar 2025).
- It has raised $129.3M across 6 recorded rounds; the latest was Early Stage VC ($35.0M) in Mar 2025.
- Notable investors include Insight Partners (New York), Flybridge (New York), TEDCO, Hitachi Ventures, Fusion Fund — 26 tracked in total.
- Proscia has filed 8 Form Ds with the SEC since 2014, most recently Mar 2025 ($35.0M sold to 21 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 6 rounds
- ·The complete investor list — 26 names
- ·Watchlist + deal alerts for Proscia
Funding rounds
6 roundsAbout Proscia
Developer of a digital pathology platform designed to enhance cancer diagnosis. The company's platform uses computing technologies that unlock hidden data not visible to the human eye and turn that data into valuable insights, enabling physicians to improve patient outcomes and accelerate the development of life-saving advances.
- Sector
- Healthcare
- HQ
- Philadelphia, PA, United States
- Founded
- 2014
- Employees
- 129
- Website
- proscia.com/
- Ownership
- Privately Held (backing)
Proscia doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Proscia shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Proscia in its N-PORT filings yet. We sweep new filings monthly.